160 related articles for article (PubMed ID: 12431825)
1. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Szczepura A
Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
[TBL] [Abstract][Full Text] [Related]
2. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Evans WK
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
Tennvall GR; Fernberg JO
Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
[TBL] [Abstract][Full Text] [Related]
8. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
Minshall ME; Liepa AM
Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
[TBL] [Abstract][Full Text] [Related]
11. [Economic evaluation of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patient in an outpatient setting].
Min SH; Ko SK; Lim JY
Taehan Kanho Hakhoe Chi; 2008 Jun; 38(3):363-71. PubMed ID: 18604145
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S; Goa KL
Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.
Dooms CA; Lievens YN; Vansteenkiste JF
Eur Respir J; 2006 May; 27(5):895-901. PubMed ID: 16481384
[TBL] [Abstract][Full Text] [Related]
18. Economic value of gemcitabine in non-small cell lung cancer.
Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Neymark N; Lianes P; Smit EF; van Meerbeeck JP
Pharmacoeconomics; 2005; 23(11):1155-66. PubMed ID: 16277550
[TBL] [Abstract][Full Text] [Related]
20. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
